Cathepsin S inhibitors: 2004 – 2010

Bibliography

• Vasiljeva O, Reinheckel T, Peters C, Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 2007;13(4):387-403
   PubMed Web of Science ®Google Scholar
• Gupta S, Singh RK, Dastidar S, Ray A. Cysteine cathepsin S as an immunomodulatory target: present and future trends. Expert Opin Ther Targets 2008;12(3):291-9
   PubMed Web of Science ®Google Scholar
• Wiener JJM, Sun S, Thurmond RL. Recent advances in the design of cathepsin S inhibitors. Curr Top Med Chem 2010;10(7):717-32
   PubMed Web of Science ®Google Scholar
• Nakagawa TY, Brissette WH, Lira PD, Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999;10(2):207-17
   PubMed Web of Science ®Google Scholar
• Shi G-P, Villadangos JA, Dranoff G, Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 1999;10(2):197-206
   PubMed Web of Science ®Google Scholar
• Podolin PL, Bolognese BJ, Carpenter DC, Inhibition of invariant chain processing, antigen-induced proliferative responses, and the development of collagen-induced arthritis and experimental autoimmune encephalomyelitis by a small molecule cysteine protease inhibitor. J Immunol 2008;180(12):7989-8003
   PubMed Web of Science ®Google Scholar
• Biroc SL, Gay S, Hummel K, Cysteine protease activity is up-regulated in inflamed ankle joints of rats with adjuvant-induced arthritis and decreases with in vivo administration of a vinyl sulfone cysteine protease inhibitor. Arthritis Rheum 2001;44(3):703-11
   PubMedGoogle Scholar
• Riese RJ, Mitchell RN, Villadangos JA, Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 1998;101(11):2351-63
   PubMed Web of Science ®Google Scholar
• Clark AK, Yip PK, Grist J, Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci USA 2007;104(25):10655-60
   PubMed Web of Science ®Google Scholar
• Teupser D, Pavlides S, Tan M, Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci USA 2004;101(51):17795-800
   PubMed Web of Science ®Google Scholar
• Sukhova GK, Zhang Y, Pan J-H, Deficiency of cathepsin S reduces atherosclerosis in LDL receptor–deficient mice. J Clin Invest 2003;111(6):897-906
   PubMed Web of Science ®Google Scholar
• Shi G-P, Suknhova GK, Kuzuya M, Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res 2003;92(5):493-500
   PubMed Web of Science ®Google Scholar
• Wang B, Sun J, Kitamoto S, Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 2006;281(9):6020-9
   PubMed Web of Science ®Google Scholar
• Pauly TA, Sulea T, Ammirati M, Specificity determinants of human cathepsin S revealed by crystal structures of complexes. Biochemistry 2003;42(11):3203-13
   PubMed Web of Science ®Google Scholar
• Gauthier JY, Black WC, Courchesne I, The identification of potent, selective, and bioavailable cathepsin S inhibitors. Bioorg Med Chem Lett 2007;17(17):4929-33
   PubMed Web of Science ®Google Scholar
• Cai J, Bennett DJ, Rankovic Z, 2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors. Bioorg Med Chem Lett 2010;20(15):4447-50
   PubMed Web of Science ®Google Scholar
• Irie O, Ehara T, Iwasaki A, Discovery of selective and nonpeptidic cathepsin S inhibitors. Bioorg Med Chem Lett 2008;18(14):3959-62
   PubMed Web of Science ®Google Scholar
• Liu H, Tully DC, Epple R, Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1. Bioorg Med Chem Lett 2005;15(22):4979-84
   PubMed Web of Science ®Google Scholar
• Leroy V, Thurairatnam S. Cathepsin S inhibitors. Expert Opin Ther Patents 2004;14(3):301-11
   Web of Science ®Google Scholar
• Thurmond RL, Sun S, Karlsson L, Edwards JP. Cathepsin S inhibitors as novel immunomodulators. Curr Opin Investig Drugs 2005;6(5):473-82
   PubMedGoogle Scholar
• Link JO, Zipfel S. Advances in cathepsin S inhibitor design. Curr Opin Drug Discov Dev 2006;9(4):471-82
   PubMedGoogle Scholar
• Maryanoff BE, Costanzo MJ. Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem 2008;16(4):1562-95
   PubMed Web of Science ®Google Scholar
• Fusion Antibodies Limited. Therapy. WO2007128987; 2007
   Google Scholar
• Fusion Antibodies Limited. Antibody and uses thereof. WO2008044076; 2008
   Google Scholar
• Elie BT, Gocheva V, Shree T, Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochemie 2010;92(11):1618-24
   PubMed Web of Science ®Google Scholar
• Medivir UK Ltd & Peptimmune, Inc. Furanone derivatives as inhibitors of cathepsin S. WO200069855; 2000
   Google Scholar
• Medivir UK Ltd & Peptimmune, Inc. C-5 substituted furanone dipeptide cathepin S inhibitors. WO2005082876; 2005
   Google Scholar
• Medivir UK Ltd & Peptimmune, Inc. Cathepsin S inhibitors. WO2006064286; 2006
   Google Scholar
• Ayesa S, Lindquist C, Agback T, Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors of cathepsin S: effect of sulfonamides P3 substituents on potency and selectivity. Bioorg Med Chem 2009;17(3):1307-24
   PubMed Web of Science ®Google Scholar
• Medivir AB. Bicyclic compounds useful as cathepsin S inhibitors. WO2007144379; 2007
   Google Scholar
• Medivir AB. Protease inhibitors. WO2010034788; 2010
   Google Scholar
• Medivir AB. Protease inhibitors. WO2010034789; 2010
   Google Scholar
• Medivir AB. Protease inhibitors. WO2010034790; 2010
   Google Scholar
• Medivir AB. Project Portfolio. Available from: http://www.medivir.se/v4/en/
   Google Scholar
• Amura Therapeutics Limited. Furo[3,2-B]pyrrole-3-ones as cathepsin S inhibitors. WO2009112826; 2009
   Google Scholar
• Amura Therapeutics Limited. Compounds. WO2009112839; 2009
   Google Scholar
• Amura Therapeutics Limited. Tetrahydrofuro[3,2-B]pyrrole-3-one derivatives as inhibitors of cysteine proteases. WO2009144450; 2009
   Google Scholar
• Amura reports antigen presentation study results. Available from: http://www.amura.co.uk/news.asp; April 7, 2009
   Google Scholar
• Amura announces positive results in chronic neuropathic pain model. Available from: http://www.amura.co.uk/news.asp; April 7, 2009
   Google Scholar
• Amura reports rheumatoid arthritis study results. Available from: http://www.amura.co.uk/news.asp; September 1, 2009
   Google Scholar
• IRM LLC (Novartis Genomics Institute). Compounds and compositions as cathepsin S inhibitors. WO2005107464; 2005
   Google Scholar
• IRM LLC (Novartis Genomics Institute). Inhibitors of cathepsin S. WO2005039496; 2005
   Google Scholar
• Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1beta converting enzyme. US6103711; 2000
   Google Scholar
• Cytovia, Inc. Caspase inhibitors and the use thereof. US6716818; 2004
   Google Scholar
• Axys Pharmaceuticals, Inc. (Celera Genomics). Haloalkyl containing compounds as cysteine protease inhibitors. WO2005028454; 2005
   Google Scholar
• Axys Pharmaceuticals, Inc. (Celera Genomics). Amidino compounds as cysteine protease inhibitors. WO2005063742; 2005
   Google Scholar
• Axys Pharmaceuticals, Inc. (Celera Genomics). Silinane compounds as cysteine protease inhibitors. WO2005074904; 2005
   Google Scholar
• Applera Corporation (Celera Genomics). Alpha ketoamide compounds as cysteine protease inhibitors. WO2006102243; 2006
   Google Scholar
• Applera Corporation (Celera Genomics). Alpha ketoamide compounds as cysteine protease inhibitors. WO2006102423; 2006
   Google Scholar
• Virobay, Inc. Compounds that inhibit protease cathepsin S and HCV replication. WO2009055467; 2009
   Google Scholar
• 4SC AG. Inhibitors of cancer cell, T-cell and keratinocyte proliferation. WO2007017284; 2007
   Google Scholar
• Wood WJL, Patterson AW, Tsuruoka H, Substrate activity screening: A fragment-based method for the rapid identification of nonpeptidic protease inhibitors. J Am Chem Soc 2005;127(44):15521-7
   PubMed Web of Science ®Google Scholar
• Patterson AW, Wood WJL, Ellman JA. Substrate activity screening (SAS): a general procedure for the preparation and screening of a fragment-based non-peptidic protease substrate library for inhibitor discovery. Nat Protocols 2007;2(2):424-33
   PubMed Web of Science ®Google Scholar
• Patterson AW, Wood WJL, Hornsby M, Identification of selective, nonpeptidic nitrile inhibitors of cathepsin S using the substrate activity screening method. J Med Chem 2006;49(21):6298-307
   PubMed Web of Science ®Google Scholar
• Inagaki H, Tsuruoka H, Hornsby M, Characterization and optimization of selective, nonpeptidic inhibitors of cathepsin S with an unprecedented binding mode. J Med Chem 2007;50(11):2693-9
   PubMed Web of Science ®Google Scholar
• Aventis Pharmaceuticals, Inc. (Sanofi-aventis). Novel keto-oxadiazole derivatives as cathepsin inhibitors. WO2005040142; 2005
   Google Scholar
• Sanofi-aventis. Spirocyclic nitriles as protease inhibitors. WO2007137738; 2007
   Google Scholar
• Sanofi-aventis. Spirocyclic nitriles as protease inhibitors. US20090275523; 2009
   Google Scholar
• Merck Frosst Canada & Axys Pharmaceuticals. Cathepsin cysteine protease inhibitors. WO2003075836; 2003
   Google Scholar
• Merck Frosst Canada. Cathepsin cysteine protease inhibitors. WO2005019161; 2005
   Google Scholar
• Merck Frosst Canada. Cathepsin inhibitors. WO2005021487; 2005
   Google Scholar
• Merck Frosst Canada. Cathepsin cysteine protease inhibitors. WO2005056529; 2005
   Google Scholar
• Merck Frosst Canada. Cathepsin cysteine protease inhibitors. WO2006056047; 2006
   Google Scholar
• Gauthier JY, Chauret N, Cromlish W, The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008;18(3):923-8
   PubMed Web of Science ®Google Scholar
• Axys Pharmaceuticals, Inc. (Celera Genomics). Compounds and compositions as protease inhibitors. US6576630; 2003
   Google Scholar
• Merck Frosst Canada. Prodrugs of inhibitors of cathepsin S. WO2008028301; 2008
   Google Scholar
• Merck Frosst Canada. Fluoroalkylamines derivatives as cathepsin S inhibitors. WO2006128287; 2006
   Google Scholar
• Axys Pharmaceuticals, Inc. (Celera Genomics). Haloalkyl containing compounds as cysteine protease inhibitors. WO2005028429; 2005
   Google Scholar
• Axys Pharmaceuticals, Inc. (Celera Genomics). Polymorphs of the cysteine protease inhibitor N-(1-cyanocyclopropyl)-3-cyclopropylmethansulfonyl-2 (R)-(2,2,2-trifluoro-1 (S)-(4-fluorophenyl)-ethylamino) propionamide. WO2006034006; 2006
   Google Scholar
• Axys Pharmaceuticals, Inc. (Celera Genomics). Processes and intermediates for preparing cysteine protease inhibitors. WO2006034004; 2006
   Google Scholar
• Axys Pharmaceuticals, Inc. (Celera Genomics). Sulfonamide compounds as cysteine protease inhibitors. WO2006060810; 2006
   Google Scholar
• Applera Corp. (Celera Genomics). Sulfonyl containing compounds as cysteine protease inhibitors. WO2006102535; 2006
   Google Scholar
• Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors. WO2008042968; 2008
   Google Scholar
• Axys Pharmaceuticals, Inc. (Celera Genomics). Haloalkyl containing compounds as cysteine protease inhibitors. WO2006060494; 2006
   Google Scholar
• Celera Genomics initiates Phase I clinical trial for cathepsin S inhibitor for the treatment of psoriasis. Available from: https://www.celera.com/celera/pr_1127168705; September 20, 2005
   Google Scholar
• Celera Genomics announces the sale of its cathepsin S inhibitor program to Schering AG. Available from: https://www.celera.com/celera/pr_1152570053; June 21, 2006
   Google Scholar
• AstraZeneca AB. Novel compounds. WO2004000825; 2003
   Google Scholar
• AstraZeneca AB. Cathepsin cysteine protease inhibitors and their use. WO2004054987; 2004
   Google Scholar
• Asaad N, Bethel PA, Coulson MD, Dipeptidyl nitrile inhibitors of cathepsin L. Bioorg Med Chem Lett 2009;19(15):4280-3
   PubMed Web of Science ®Google Scholar
• Bethel PA, Gerhardt S, Jones EV, Design of selective cathepsin inhibitors. Bioorg Med Chem Lett 2009;19(16):4622-5
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors. WO2004083182; 2004
   Google Scholar
• Korea Research Institute of Chemical Technology. Novel carbonitrile compounds, process for preparing thereof, and pharmaceutical composition for treating or preventing articular rheumatism, osteoarthritis, Paget's disease, hypercalcemia of malignancy, metabolic bone disease and cancers comprising the same. KR2009005842; 2009
   Google Scholar
• Song JH, Kim SG, No ZS, Discovery and synthesis of novel N-cyanopyrazolidine and N-cyanohexahydropyridazine derivatives as cathepsin inhibitors. Bull Korean Chem Soc 2008;29(8):1467-71
   Web of Science ®Google Scholar
• AstraZeneca AB. New use of pyrimidine- or triazine-2-carbonitriles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitrile derivatives. WO2004000819; 2003
   Google Scholar
• AstraZeneca AB. Novel purine- or pyrrolol[2,3-d]pyrimidine-2-carbonitriles for treating diseases associated with cysteine protease activity. WO2004000843; 2003
   Google Scholar
• AstraZeneca UK Limited. Pteridine derivatives and their use as cathepsin inhibitors. WO2007148064; 2007
   Google Scholar
• Morley AD, Kenny PW, Burton B, 5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors. Bioorg Med Chem Lett 2009;19(6):1658-61
   PubMed Web of Science ®Google Scholar
• Novartis-Pharma GMBH. Pyrrolo pyrimidines as agents for the inhibition of cysteine protease. WO2003020721; 2003
   Google Scholar
• Novartis-Pharma GMBH. Spiro-substituted pyrrolopyrimidines. WO2004076455; 2004
   Google Scholar
• Teno N, Miyake T, Ehara T, Novel scaffold for cathepsin K inhibitors. Bioorg Med Chem Lett 2007;17(22):6096-100
   PubMed Web of Science ®Google Scholar
• Novartis-Pharma GMBH. 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof. WO2004069256; 2004
   Google Scholar
• Irie O, Kosaka T, Ehara T, Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain. J Med Chem 2008;51(18):5502-5
   PubMed Web of Science ®Google Scholar
• Novartis-Pharma GMBH. Compounds and compositions useful as cathepsin S inhibitors. WO2006018284; 2006
   Google Scholar
• Novartis-Pharma GMBH. Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases. WO2003020278; 2003
   Google Scholar
• Altmann E, Aichholz R, Betschart C, 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K. J Med Chem 2007;50(4):591-4
   PubMed Web of Science ®Google Scholar
• Irie O, Yokokawa F, Ehara T, 4-Amino-2-cyanopyrimidines: novel scaffold for nonpeptidic cathepsin S inhibitors. Bioorg Med Chem Lett 2008;18(16):4642-6
   PubMed Web of Science ®Google Scholar
• Irie O, Kosaka T, Kishida M, Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2. Bioorg Med Chem Lett 2008;18(19):5280-4
   PubMed Web of Science ®Google Scholar
• N.V. Organon. 4-Phenyl-pyrimidine-2-carbonitrile derivatives. WO2005121106; 2005
   Google Scholar
• N.V. Organon. 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives. WO2007039470; 2007
   Google Scholar
• Rankovic Z, Cai J, Kerr J, Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett 2010;20(5):1524-7
   PubMed Web of Science ®Google Scholar
• Cai J, Fradera X, van Zeeland M, 4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important. Bioorg Med Chem Lett 2010;20(15):4507-10
   PubMed Web of Science ®Google Scholar
• Falgueyret J-P, Desmarais S, Oballa R, Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem 2005;48(24):7535-43
   PubMed Web of Science ®Google Scholar
• N.V. Organon. 6-Phenyl-1H-Imidazo[4, 5-C]pyridine-4-carbonitrile derivatives as cathepsin K and S inhibitors. WO2007080191; 2007
   Google Scholar
• N.V. Organon. 6-Phenyl-1H-Imidazo[4, 5-C]pyridine-4-carbonitrile derivatives as cathepsin inhibitors. WO2009010491; 2009
   Google Scholar
• Cai J, Baugh M, Black D, 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors. Bioorg Med Chem Lett 2010;20(15):4350-4
   PubMed Web of Science ®Google Scholar
• Oballa RM, Truchon J-F, Bayly CI, A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds. Bioorg Med Chem Lett 2007;17(4):998-1002
   PubMed Web of Science ®Google Scholar
• Sunesis Pharmaceuticals. Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin S. WO2008100618; 2008
   Google Scholar
• Sunesis Pharmaceuticals. Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin S. WO2008100621; 2008
   Google Scholar
• Sunesis Pharmaceuticals. Biaryl substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin S. WO2008100622; 2008
   Google Scholar
• Sunesis Pharmaceuticals. Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin S. WO2008100620; 2008
   Google Scholar
• Sunesis Pharmaceuticals. 1-[3-(Monocyclic amino)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]-pyridines as modulators of cathepsin S. WO2008100635; 2008
   Google Scholar
• Ameriks MK, Axe FU, Bembenek SD, Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements. Bioorg Med Chem Lett 2009;19(21):6131-4
   PubMed Web of Science ®Google Scholar
• Wiener DK, Lee-Dutra A, Bembenek S, Thioether acetamides as P3 binding elements for tetrhydropyrido-pyrazole cathepsin S inhibitors. Bioorg Med Chem Lett 2010;20(7):2379-82
   PubMed Web of Science ®Google Scholar
• Ameriks MK, Bembenek SD, Burdett MT, Diazinones as P2 replacements for pyrazole-based cathepsin S inhibitors. Bioorg Med Chem Lett 2010;20(14):4060-4
   PubMed Web of Science ®Google Scholar
• Ameriks MK, Cai H, Edwards JP, Pyrazole-based arylalkyne cathepsin S inhibitors. Part II: optimization of cellular potency. Bioorg Med Chem Lett 2009;19(21):6135-9
   PubMed Web of Science ®Google Scholar
• Lee-Dutra A, Wiener DK, Arienti KL, Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: Part 1. Bioorg Med Chem Lett 2010;20(7):2370-4
   PubMed Web of Science ®Google Scholar
• Wiener JJM, Wickboldt AT, Wiener DK, Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors. Part 2: modification of P3, P4 and P5 regions. Bioorg Med Chem Lett 2010;20(7):2375-8
   PubMed Web of Science ®Google Scholar
• NCT00396422: study to investigate the safety, tolerability, absorption, distribution, metabolism, and elimination of RWJ-445380 administered to patients with plaque psoriasis. Available from: www.clinicaltrials.gov; November 2006
   Google Scholar
• NCT00425321: safety and effectiveness study of RWJ-445380 cathepsin-S inhibitor in patients with active rheumatoid arthritis despite methotrexate therapy. Available from: www.clinicaltrials.gov; April 2007
   Google Scholar
• Sunesis Pharmaceuticals announces milestone payment from inflammation collaboration. Available from: http://ir.sunesis.com/releasedetail.cfm?ReleaseID=295117; February 20, 2008
   Google Scholar
• IRM L.L.C. (Novartis Genomics Institute). Inhibitors of cathepsin S. WO2004084842; 2004
   Google Scholar
• IRM L.L.C. (Novartis Genomics Institute). Inhibitors of cathepsin S. WO2004084843; 2004
   Google Scholar
• IRM L.L.C. (Novartis Genomics Institute). Inhibitors of cathepsin S. WO2004112709; 2004
   Google Scholar
• Altmann E, Renaud J, Green J, Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors. J Med Chem 2002;45(12):2352-4
   PubMed Web of Science ®Google Scholar
• Altmann E, Green J, Tintelnot-Blomley M. Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K—investigating P1' substituents. Bioorg Med Chem Lett 2003;13(12):1997-2001
   PubMed Web of Science ®Google Scholar
• Alper PB, Liu H, Chatterjee AK, Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: optimization of P1 and N-aryl. Bioorg Med Chem Lett 2006;16(6):1486-90
   PubMed Web of Science ®Google Scholar
• Tully DC, Liu H, Alper PB, Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: Heterocyclic P3. Bioorg Med Chem Lett 2006;16(7):1975-80
   PubMed Web of Science ®Google Scholar
• IRM L.L.C. (Novartis Genomics Institute). Inhibitors of cathepsin S. WO2005018568; 2005
   Google Scholar
• IRM L.L.C. (Novartis Genomics Institute). Inhibitors of cathepsin S. WO2005034848; 2005
   Google Scholar
• Tully DC, Liu H, Chatterjee AK, Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers. Bioorg Med Chem Lett 2006;16(19):5112-17
   PubMed Web of Science ®Google Scholar
• Tully DC, Liu H, Chatterjee AK, Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors. Bioorg Med Chem Lett 2006;16(19):5107-11
   PubMed Web of Science ®Google Scholar
• Chatterjee AK, Liu H, Tully DC, Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S. Bioorg Med Chem Lett 2007;17(10):2899-903
   PubMed Web of Science ®Google Scholar